OpenNashPodcasts

Person

Bob Nelsen

This page collects what Bob Nelsen said on episode 87 of The Long Run with Luke Timmerman, a podcast about biotech investing, where he spoke as a representative of ARCH Venture Partners. Topics include how ARCH builds companies, drug manufacturing, Alzheimer's treatment and the response to COVID-19.

Nelsen says ARCH incubates new companies inside existing portfolio companies, and that it has banned the phrase "news flow". He also says Resilience should become the obvious outsourcing choice for biologic manufacturing. In 2021, he said the pandemic response was inadequate, and predicted the United States would reach herd immunity first. Each fact below links to the moment it was said.

1 episodes · 16 quoted claims

Bob Nelsen cites Prime as a company incubated within Beam as an example of ARCH's company-within-company model.

“Well, I think an example would be that Prime is kind of has incubated within Beam.”

The Long Run with Luke Timmerman · 0:10:41

Bob Nelsen contrasts Flagship Pioneering's incubation of companies within Flagship with ARCH's model of incubating companies within existing portfolio companies.

“While Flagship might incubate companies, a bunch of companies within Flagship, we have a model that's kind of incubating companies within companies.”

The Long Run with Luke Timmerman · 0:10:41

Bob Nelsen says the Japanese government appointed a minister of loneliness, citing it amid concern about suicides in Japan.

“I think the Japanese government just appointed a minister of loneliness.”

The Long Run with Luke Timmerman · 0:15:03

Bob Nelsen says people with two copies of the APOE4 gene variant, which he calls APOE44, are probably going to get Alzheimer's disease.

“We know if you have an APOE44, you're probably going to get it.”

The Long Run with Luke Timmerman · 0:18:20

Bob Nelsen suggests cell therapy companies could run their own treatment centers next to hospitals, owned by the company that manufactures the cells.

“maybe you create a cell therapy center that sits next to a big hospital but it's it's you know essentially owned by the company that's manufacturing the cells.”

The Long Run with Luke Timmerman · 0:21:27

Bob Nelsen argues the world's pandemic response was inadequate, noting it took about a year and roughly half a million deaths in the US to reach vaccines.

“It only took a year and a half a million dead people, right?”

The Long Run with Luke Timmerman · 0:23:30

Bob Nelsen says Resilience should become the obvious outsourcing choice for biologic manufacturing, using TSMC as a model.

“obvious that you should work with us versus doing it yourself and you know tsmc is a good model for that”

The Long Run with Luke Timmerman · 0:26:18

Bob Nelsen says the semiconductor industry's heavy investment in better, faster, cheaper manufacturing drove the entire computer industry, and biotech can learn from that.

“they actually invest a lot of money um and technology figuring out how to make stuff uh way better faster cheaper and that's what drove the entire computer industry”

The Long Run with Luke Timmerman · 0:26:18

Bob Nelsen questions whether antibodies must be made in large steel tanks and suggests making them inside the body instead.

“Do we have to make antibodies in big giant steel tanks? Maybe we should make them in the body.”

The Long Run with Luke Timmerman · 0:27:13

Bob Nelsen says an immortalized B cell could, in principle, supply all the vaccines a person would ever need.

“if I can make an immortalized B cell I could give you all of the vaccines you would ever need in your lifetime”

The Long Run with Luke Timmerman · 0:28:35

Bob Nelsen says the biggest threat to the biotech industry was the drug-pricing agenda of Elizabeth Warren and Bernie Sanders, which he says did not come to pass.

“the big threat to the industry was the Elizabeth Warren crazy, Bernie Sanders crazy, you know, see crazy that, you know, don't really understand innovation is actually the solution to public health, not the problem.”

The Long Run with Luke Timmerman · 0:31:04

Bob Nelsen argues that requiring five-to-ten-year trials instead of using surrogate endpoints for Alzheimer's and Parkinson's drugs is unreasonable.

“we can't, you know, develop intermediate markers for Alzheimer's or Parkinson's or, you know, other chronic and debilitating disease and that we have to have, you know, five or 10 year long clinical development cycles is just crazy.”

The Long Run with Luke Timmerman · 0:36:47

Bob Nelsen says ARCH typically spends about a month trying to reduce the size of a company's financing round to raise the minimum needed from the best investors.

“And almost certainly we spent like a month trying to cut back the size of the round.”

The Long Run with Luke Timmerman · 0:39:48

Bob Nelsen says Sana Biotechnology's successful IPO as a preclinical company reflected investors who evaluated the data and long-term potential rather than short-term news flow.

“well, how is Sana so successful in their IPO being a preclinical company, right? It's because people actually looked at the data and thought about where they could be in five or ten years.”

The Long Run with Luke Timmerman · 0:41:50

Bob Nelsen predicted the United States would reach herd immunity against COVID-19 before other major countries because of its strong vaccines and low mask compliance.

“the fact that we have the best vaccine and the stupidest group of people that don't wear masks will conspire together to have the U.S. reach herd immunity probably before any other major country.”

The Long Run with Luke Timmerman · 0:44:36